Profile
Mads Dalsgaard has a current job as an Independent Director at AptaTargets SL since 2018.
Mads Dalsgaard active positions
Companies | Position | Start |
---|---|---|
AptaTargets SL
AptaTargets SL Pharmaceuticals: MajorHealth Technology AptaTargets SL is a biopharmaceutical company based in Madrid, Spain that focuses on developing therapeutic applications based on aptamer technology. The Spanish company is currently developing aptoll, an immune modulator that blocks the activation of tlr4 in a stroke, representing a novel approach to treat ischemic stroke in the acute phase. It could also be administered in patients up to 48 hours after the stroke. AptaTargets targets indications where inflammation causes significant damage through clinical studies and successful preclinical development. The company was founded in 2014 by David Segarra and María Eugenia Zarabozo, with David Segarra serving as the CEO since then. | Director/Board Member | 2018-05-31 |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 1 |
---|---|
AptaTargets SL
AptaTargets SL Pharmaceuticals: MajorHealth Technology AptaTargets SL is a biopharmaceutical company based in Madrid, Spain that focuses on developing therapeutic applications based on aptamer technology. The Spanish company is currently developing aptoll, an immune modulator that blocks the activation of tlr4 in a stroke, representing a novel approach to treat ischemic stroke in the acute phase. It could also be administered in patients up to 48 hours after the stroke. AptaTargets targets indications where inflammation causes significant damage through clinical studies and successful preclinical development. The company was founded in 2014 by David Segarra and María Eugenia Zarabozo, with David Segarra serving as the CEO since then. | Health Technology |
- Stock Market
- Insiders
- Mads Dalsgaard